News Headlines Article

Gilead raids Genentech to add to cancer ranks
San Francisco Business Times

Gilead Sciences Inc., coming off its first cancer drug approval and with more in its portfolio, hired Dr. Philippe Bishop away from Genentech Inc. to head its cancer drug programs.

Bishop since 2007 had been vice president of oncology product development at South San Francisco-based Genentech, running dozens of drugs through hundreds of clinical trials. That list includes the blockbuster breast cancer drug Avastin, the antibody-drug conjugate Kadcyla, a $10,000-a-month drug that targets breast cancer, and another breast cancer drug, Perjeta.